Japan’s high-tech healthcare system relies heavily on hematology analyzers, which automate blood analysis that translates to faster diagnoses and targeted treatment for a wide range of blood conditions. Against this backdrop, Japan’s hematology analyzers market is expected to grow at a compound annual growth rate (CAGR) of around 5% through 2033, forecasts GlobalData, a leading data and analytics company.

GlobalData reveals that Japan’s hematology analyzers market accounted for around 70% of the Asia-Pacific market in 2023, driven by the availability of advanced technology from some of the prominent companies such as Horiba Ltd, Sysmex Corp, Nihon Kohden Corp.

Horiba has recently unveiled correlated rouleaux analysis (CoRA) technology integrated into its three latest analyzers. This addition enhances the instruments’ existing functionality with a comprehensive profile for assessing inflammatory diseases.

Shreya Jain, Medical Devices Analyst at GlobalData, comments: “The utilization of hematology analyzers has been bolstered by their ability to provide accurate diagnostic information, supporting efficient healthcare delivery. However, the cost and turnaround time limitations with these analyzers restrict comprehensive testing due to financial strain on healthcare facilities and operational inefficiencies, delaying diagnoses and treatments.”

Horiba’s patented CoRA technology combines CBC and 5-population white blood cell differentiation with rapid erythrocyte sedimentation rate, into one compact analyzer and offers test results from whole blood in 60 seconds. This integration is said to reduce costs per test, decrease turnaround times, and conserve valuable laboratory space.

Jain concludes: “By addressing the current limitations and prioritizing sustainability, Japan is set to revolutionize hematological diagnostics, ensuring high-quality, accessible healthcare for all. Transformative advancements in future are likely to be driven by the integration of AI, enhanced automation, and the development of portable, point-of-care devices.”